Parallel importation of medicines is an issue of great interest to pharmaceutical stakeholders, particularly importers, distributors, and pharmacies operating in an increasingly competitive and regulated environment.
In Switzerland, this practice is permitted but subject to strict requirements set by Swissmedic and the federal regulatory framework. Understanding what is actually allowed and what the critical issues are is essential to avoid regulatory risks and ensure patient safety.
What is parallel importation of drugs
Parallel importation is the introduction of a medicine already authorized in another country into the Swiss market without the direct consent of the original authorization holder.
This practice is based on the principle of free movement of goods, but in the pharmaceutical sector it is severely limited by safety, quality and efficacy requirements.
In other words, this is not just a commercial activity: each product must meet standards equivalent to those required for medicines authorized in Switzerland.
The Swiss regulatory framework
In Switzerland, parallel import is mainly regulated by:
- the Therapeutic Agents Act (LATer)
- related ordinances
- The guidelines and requirements established by Swissmedic
A general overview of the Swiss regulatory system can be found on Swissmedic’s official website:
https://www.swissmedic.ch
The normative reference text (LATer) is available on the federal portal:
https://www.fedlex.admin.ch
Unlike the European Union, where there is a more structured and harmonized system, Switzerland takes a more restrictive approach.
Mandatory authorization
Those wishing to carry out parallel import must obtain specific authorization from Swissmedic.
The key requirement is to demonstrate that the imported medicine is identical or essentially equivalent to a product already authorized in Switzerland.
Parallel import requirements
In order to operate legally, importers must meet several basic requirements.
1. Equivalence of the drug
The imported product must have:
- the same active ingredient
- the same pharmaceutical form
- the same dosage
- An equivalent qualitative and quantitative composition
Even minor differences can lead to rejection of the request.
2. Quality and safety
It is necessary to ensure that the medicine:
- Is produced in accordance with Good Manufacturing Practices (GMP)
- Maintain the same quality as the product authorized in Switzerland
- Is traceable throughout the supply chain
3. Labeling and information
Therefore, the product must be adapted to the Swiss market:
- labeling in accordance with official languages
- approved package insert
- Information consistent with the authorized file
4. Import authorization
The operator must possess:
- import authorization
- adequate quality system
- qualified responsible person
For more information on permits and activities subject to inspection, please see:
https://www.swissmedic.ch
The main critical regulatory issues
Despite the theoretical possibility, parallel import into Switzerland has several operational criticalities.
Authorization complexity
The approval process can be lengthy and requires detailed documentation. The assessment of equivalence is not always straightforward and can vary on a case-by-case basis.
Differences from the EU
Many practitioners make the mistake of applying European logic to the Swiss context.
Actually:
- there is no automatic mutual recognition
- Swissmedic conducts an independent assessment
- requirements may be more stringent
Risks of non-compliance
Errors in parallel import management can result in:
- regulatory sanctions
- withdrawal of products from the market
- reputational damage
Supply chain management
Ensuring traceability and quality throughout the distribution chain is particularly complex, especially when products come from different markets.
When does it really pay off?
Parallel import can represent an opportunity in terms of:
- cost reduction
- increased competitiveness
- access to certain products
However, it is sustainable only if:
- volume justifies regulatory costs
- there is an appropriate organizational structure
- regulatory risk is under control
Conclusion
Parallel import of drugs into Switzerland is a real possibility, but not without its complexities.
Operating in this field requires:
- A deep understanding of the regulatory framework
- strict quality management
- a well-defined strategy
Only a structured approach can turn this opportunity into a real competitive advantage, avoiding risk and ensuring patient safety.